Sanjay Ratnakant, MD
Sleep Medicine · Southaven, MSNPI 1578569935
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.1% of the total across 102 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 29 manufacturers reported payments, led by AstraZeneca at 25.6% of the total.
Across 102 payments — averaging $23.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$620
- Harmony Biosciences LLC$391
- Avadel CNS Pharmaceuticals, LLC$249
- ZOLL Respicardia, Inc.$173
- Genentech USA, Inc.$81
- Boehringer Ingelheim$79
- plus $825 from 23 others
What the payments were for
- Food & beverage$2,20391%
- Education$2159%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 29 | $620 |
| Harmony Biosciences LLC | 7 | $391 |
| Avadel CNS Pharmaceuticals, LLC | 10 | $249 |
| ZOLL Respicardia, Inc. | 3 | $173 |
| Genentech USA, Inc. | 5 | $81 |
| Boehringer Ingelheim | 4 | $79 |
| Jazz Pharmaceuticals Inc. | 3 | $65 |
| Novartis | 3 | $64 |
| GSK | 3 | $62 |
| Mylan Specialty L.p. | 3 | $58 |
| Axsome Therapeutics, Inc. | 2 | $53 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $47 |
| Grifols USA, LLC | 3 | $46 |
| Sunovion Pharmaceuticals Inc. | 3 | $44 |
| Philips North America LLC | 3 | $43 |
| AbbVie(2 entities) | 2 | $39 |
| United Therapeutics Corporation | 2 | $37 |
| Gilead | 2 | $36 |
| Amgen | 2 | $34 |
| Merck | 2 | $34 |
| Paratek Pharmaceuticals, Inc. | 1 | $25 |
| Advanced Respiratory, Inc | 1 | $21 |
| Mallinckrodt Enterprises LLC | 1 | $21 |
| Johnson & Johnson | 1 | $21 |
| Regeneron Healthcare Solutions, Inc. | 1 | $20 |
| Insmed, Inc. | 1 | $15 |
| Shire North American Group Inc | 1 | $14 |
| Mallinckrodt Hospital Products Inc. | 1 | $13 |
| Veran Medical Technologies, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- remede System$141
How this compares
Too few sleep medicine providers in Mississippito place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 321 | $259,029 |
| XywavSodium,calcium,mag,pot Oxybate | 15 | $154,300 |
| Ambrisentan | 25 | $53,595 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 51 | $47,044 |
| Spiriva RespimatTiotropium Bromide | 44 | $38,206 |
| Spiriva HandihalerTiotropium Bromide | 19 | $26,428 |
| SymbicortBudesonide/Formoterol Fumarate | 48 | $23,028 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 112 | $22,521 |
| Advair HfaFluticasone Propion/Salmeterol | 39 | $18,628 |
| Breo ElliptaFluticasone/Vilanterol | 25 | $13,630 |
| XareltoRivaroxaban | 22 | $11,320 |
| DuleraMometasone/Formoterol | 18 | $10,682 |
| Tiotropium Bromide | 15 | $9,386 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 12 | $7,774 |
| Wixela InhubFluticasone Propion/Salmeterol | 23 | $4,498 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $62 | $272,658346 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $620 | $70,07199 claims |
| Boehringer IngelheimSpiriva Respimat, Combivent Respimat | $79 | $45,98156 claims |
| Johnson & JohnsonXarelto | $21 | $11,32022 claims |
| MerckDulera | $34 | $10,68218 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few sleep medicine providers in Mississippion file to place this against a meaningful peer group, so we don't.
Other sleep medicine in Southaven
- Brenda HinesFlowood$56K
- Andrea LewisJackson$36K
- Christopher KarcherOcean Springs$26K
- John DouglasGulfport$8K
- Gowdhami MohanClarksdale$5K
- John BoswellColumbus$2K
- Kary WhiteheadMeridian$2K
- Mohammad UllahJackson$2K
- Alexandra EdwardsLaurel$1K
- Dani ChoufaniJackson$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.